Advanced BioDesign Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 25

Employees

  • Latest Deal Type
  • Later Stage VC
  • (In Progress)

  • Latest Deal Amount
  • $27.3M

  • Investors
  • 2

Advanced BioDesign General Information

Description

Developer of novel anticancer drugs designed to focus specifically on targeting ALDH (aldehyde dehydrogenase) as a therapeutic approach. The company's innovative strategy aims to overcome tumor chemoresistance and focuses on the discovery and production of recombinant molecules for myeloid leukemia, thereby enabling institutions in the field of immunology to overcome tumor chemoresistance and to restore or activate endogenous cell death mechanisms in cancer cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Parc Technologique de Lyon, Bâtiment D
  • 655 Allée des Parcs
  • 69800 Saint-Priest
  • France
+33 04 00 00 00 00

Advanced BioDesign Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Advanced BioDesign Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 29-Dec-2023 $27.3M 000.00 In Progress Clinical Trials - Phase 2
5. Later Stage VC 28-Feb-2023 000.00 000.00 Completed Clinical Trials - Phase 1
4. Grant 15-May-2023 00.000 000.00 Completed Clinical Trials - Phase 1
3. Grant 15-Nov-2021 00000 000.00 Completed Clinical Trials - Phase 1
2. Later Stage VC 25-Feb-2020 $10.1M $20.3M 000.00 Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 17-Dec-2013 $10.2M $10.2M 000.00 Completed Clinical Trials - Phase 1
To view Advanced BioDesign’s complete valuation and funding history, request access »

Advanced BioDesign Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
ADP D 000,000 00.000000 0000.00 0000.00 00 0000.00 00.000
ADP D 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
ADP D 0,000 00.000000 0000.0 0000.0 00 0000.0 0.000
ADP B 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
ADP B 00,000 00.000000 000.0 000.0 00 000.0 0.000
ADP B 89,427 $1.093096 $15.3 $15.3 1x $15.3 22.05%
ADP B 38,520 $1.093096 $10.93 $10.93 1x $10.93 9.5%
To view Advanced BioDesign’s complete cap table history, request access »

Advanced BioDesign Patents

Advanced BioDesign Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-3119314-A1 Lipid nanocapsule comprising at least one aminothiolester compound or one of its pharmaceutically acceptable derivatives Pending 29-Jan-2021 0000000000 0
EP-4035666-A1 Aminothiolester compound or derivative thereof for use as an immunomodulatory agent Inactive 29-Jan-2021 0000000000 0
AU-2022212597-A1 Aminothiolester compound or derivative thereof for use as an immunomodulatory agent Pending 29-Jan-2021 0000000000
CA-3206551-A1 Aminothiolester compound or derivative thereof for use as an immunomodulatory agent Pending 29-Jan-2021 0000000000
EP-4284360-A1 Aminothiolester compound or derivative thereof for use as an immunomodulatory agent Pending 29-Jan-2021 A61K31/265
To view Advanced BioDesign’s complete patent history, request access »

Advanced BioDesign Executive Team (4)

Name Title Board Seat Contact Info
Ismail Ceylan Co-Founder, Chief Executive Officer, President & Chairman
Guillaume Martin Co-Founder, Chief Operating Officer & Board Member
Mileidys Perez-Alea Ph.D Co-Founder, Chief Scientific Officer, Senior Scientist, Scientific Director, Member of Scientific Committee & Board Member
Patricia Findling Administrative and Financial Manager
To view Advanced BioDesign’s complete executive team members history, request access »

Advanced BioDesign Board Members (8)

Name Representing Role Since
Guillaume Martin Advanced BioDesign Co-Founder, Chief Operating Officer & Board Member 000 0000
Ismail Ceylan Advanced BioDesign Co-Founder, Chief Executive Officer, President & Chairman 000 0000
Jacques Simonnet Xerys Invest Board Member 000 0000
Pierre Le Sourd Xerys Invest Board Member 000 0000
You’re viewing 4 of 8 board members. Get the full list »

Advanced BioDesign Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Advanced BioDesign Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bpifrance Sovereign Wealth Fund 000 0000 000000 0
Xerys Invest PE/Buyout Minority 000 0000 000000 0
To view Advanced BioDesign’s complete investors history, request access »

Advanced BioDesign FAQs

  • When was Advanced BioDesign founded?

    Advanced BioDesign was founded in 2010.

  • Who is the founder of Advanced BioDesign?

    Ismail Ceylan, Guillaume Martin, and Mileidys Perez-Alea Ph.D are the founders of Advanced BioDesign.

  • Who is the CEO of Advanced BioDesign?

    Ismail Ceylan is the CEO of Advanced BioDesign.

  • Where is Advanced BioDesign headquartered?

    Advanced BioDesign is headquartered in Saint-Priest, France.

  • What is the size of Advanced BioDesign?

    Advanced BioDesign has 25 total employees.

  • What industry is Advanced BioDesign in?

    Advanced BioDesign’s primary industry is Drug Discovery.

  • Is Advanced BioDesign a private or public company?

    Advanced BioDesign is a Private company.

  • What is Advanced BioDesign’s current revenue?

    The current revenue for Advanced BioDesign is 000000.

  • How much funding has Advanced BioDesign raised over time?

    Advanced BioDesign has raised $62.9M.

  • Who are Advanced BioDesign’s investors?

    Bpifrance and Xerys Invest have invested in Advanced BioDesign.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »